

May 26, 2026

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

(ii) SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sub: Investors Presentation- Quarter IV and Financial Year ended March 31, 2026 – Orchid Pharma Limited ("the Company")

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30, Sub- Para 15 of Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 and in continuation to our earlier intimation, dated May 19, 2025, regarding the Analysts/Investors Earning Call scheduled to be held on May 26, 2026 at 04:30 P.M. (IST), please find enclosed Investors Presentation, inter-alia, including the financial performance and business information of the Company for the Quarter-IV and Financial Year ended March 31, 2026.

The Investor Presentation is also made available on the website of the Company at <https://www.orchidpharma.com/>

You are requested to take the above intimation on record.

Thanking You,
For **Orchid Pharma Limited**

Kapil Dayya
Company Secretary & Compliance Officer
Mem. No.- F10698

Encl. as above

FROM

Soil to Vial



Nature Inspired
Origins



Fermentation
& Biotransformation



KSMs & API
Process
Development



API
Manufacturing



Formulations
& Fill Finish



Finished Dosage
For A Healthier World

Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Orchid Pharma Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

One of the most **integrated** anti-infective platform globally

- ▶ Built on **30 years of cephalosporin expertise.**
- ▶ Proven by **EXBLIFEP - India's only novel antibiotic.**
- ▶ Anchored by **India's only USFDA sterile cephalosporin approval.**
- ▶ Extending into **AMR and regulated markets.**

A significantly large anti-infectives business built on an integrated foundation

Scale + Integration




A strong participant in selected high-value and regulated opportunities

Regulated Markets



Positioned for sustained long-term growth

Structural Growth



2

A differentiated cephalosporin platform spanning KSM to finished dosage

Full Value Chain



4

A business combining scale, integration, innovation and disciplined expansion

Four Pillars

An Integrated Cephalosporin Platform



Orchid is at an inflection point



The merger is nearing completion and the platform is coming together as one



The core API business is ready to create long-term value



Multiple growth engines are moving from concept to execution across KSM, FDF, and Innovative drug products

Financial Performance

FY26








FY26 Financial Performance : **Standalone**

(Rs Cr)

(Amt. in Cr.)	Q4-26	Q4-25	% Change	FY 26	FY 25	% Change
Revenue from Operations	238	237	+0%	811	922	-12%
Other Income	13	6	+117%	55	32	+72%
COGS	151	138		526	544	
Employee Exp	20	22	-9%	88	86	+2%
Other Exp	38	43	-12%	152	168	-10%
EBITDA	42	40	+5%	101	156	-36%
% to Sales	18%	17%		12%	17%	
Interest	3	4	-25%	13	15	-13%
Depreciation	9	9		36	35	
Exceptional Items	1	0		-6	0	
PAT	30	28		45	106	






Q4 FY26 Financial Performance : Standalone

(Rs Cr)



FY26 Financial Performance : Standalone


(Rs Cr)




From Turnaround to Platform Creation




The Journey of New Orchid




Revenue Growth
 ~90%
 FY 2021-26



EBITDA GROWTH
 56.8%
 FY 2021-26



₹ PAT GROWTH
 ₹141 Cr
 absolute swing
 FY 2021-26



Global Antibiotics market



Global Antibiotics market
\$45 Bn
In 2025



Growing at a
2.5% CAGR
through 2035




Cephalosporin drug market stood at
15 Billion USD
in 2025.


Out of this
15-20%
is API and ~80% is
Finished drugs

Global Antibiotic Drug Market (USD Billion)

USD Billion



Global Antibiotic Drugs by Class: 2026




Cephalosporins	32%
Penicillin	28%
Fluoroquinolone	6%
Macrolides	8%
Carbapenems	8%
Others	18%



Indian Domestic Size
~20,000 Cr




Indian Export of API and PDF
~20,000 Cr




The Merger

A Stronger, More Efficient Platform



Strategy Architecture

Cephalosporin Value Chain



Three Layers of Value Creation



Differentiated Growth Pools

Growth pools

EXBLIFEP, US FDF Generics, and differentiated products with better economics.



Value Chain Integration

Integration

Backward into 7-ACA, forward into FDF. Margin captured at every stage starting from KSM.







Core Cephalosporin API Business

Foundation

The existing business. Generates cash and funds everything above it.

Core Cephalosporin API Business The Foundation



Orchid's Role in this Market

- Core cephalosporin API is the business today- 95% of revenue
- Broadest portfolio covering 44 out of 50 Cephalosporins ever invented
- 60 Acre Facility with 5 Sterile and 7 Oral Blocks

What Orchid can Achieve from here

- Take share in regulated markets like US
- Use the API base to capture more value in FDF, 7-ACA, and Exblifep
- Improve economics per kg through process and mix discipline


Product Portfolio

	1 st Gen	2 nd Gen	3 rd Gen	4 th Gen	5 th Gen	BL - BLI
ORAL	<ul style="list-style-type: none"> ▶ Cefadroxil ▶ Cefalexin ▶ Cefradine 	<ul style="list-style-type: none"> ▶ Cefprozil ▶ Cefuroxime 	<ul style="list-style-type: none"> ▶ Cefdinir ▶ Cefditoren ▶ Cefixime ▶ Cefpodoxime ▶ Ceftibuten 	—	—	—
STERILE	<ul style="list-style-type: none"> ▶ Cefalonium ▶ Cefalothin ▶ Cefazolin 	<ul style="list-style-type: none"> ▶ Cefoxitin ▶ Ceforanide ▶ Cefotiam 	<ul style="list-style-type: none"> ▶ Cefotaxime ▶ Ceftiofur ▶ Ceftizoxime ▶ Ceftriaxone ▶ Cefoperazone ▶ Ceftazidime ▶ Cefovecin 	<ul style="list-style-type: none"> ▶ Cefepime ▶ Cefpirome ▶ Cefquinome 	<ul style="list-style-type: none"> ▶ Ceftaroline ▶ Ceftolozane ▶ Cefiderocol 	<ul style="list-style-type: none"> Cefepime + Enmetazobactam Ceftazidime + Avibactam

■ Orchid's NCE
 □ Under Development

7ACA + Downstream Strategic Integration

The Market Context and Orchid's Position



Scale
1,000 MT/yr

~75% captive consumption




Location
Kathua, Jammu

Near Punjab/J&K industrial clusters

7ACA Capacity Plan

Total Capacity: 1,000 MT



Technology
High-titer Fermentation

+ Enzymatic biocatalysis



Captive 7ACA reduces input cost - **margin flows directly to PAT**



Revenue growth driven by downstream capacity utilisation



Government incentives improve project economics — **attractive profit pool**

Orchid's Position


INDIA'S ONLY
USFDA-approved sterile
cephalosporin manufacturer.

Sterile Asset Utilisation

- ▶ Shifting sterile capacity to regulated markets, directly improves margin quality
- ▶ Each FDF unit captures more margin than API alone
- ▶ API self-supply gives Orchid a **structural cost edge** vs pure-play FDF competitors

The Market Opportunity

US market bifurcation by value



Orchid Pharma plans to launch
5-6 sterile
products in
US by 2030.

EXBLIFEP: Innovation with High-Quality Economics

India's only novel antibiotic platform creating a scalable royalty income stream



~7 Mn
Annual cUTI patients treated globally



~100 Mn vials
Total addressable market

Global cUTI Burden - Patients & Vials

Region	Population (in Million)	Number of patients in 1000s -hospitalized due to cUTI	Number of vials needed for treatment (15 vials per patient)
North America	400	240	3.6
LATAM	670	536	8.0
EUROPE	740	444	6.7
ME2AF	1890	1701	25.5
Russia/ Japan/ China	1700	1190	17.9
Rest of Asia	3160	3002	45
Total	8,560	7,113	106.7

CUTI patients per 1,000 population vary 0.4-1.0 globally

Antimicrobial Stewardship

Orchid's role in the global Antimicrobial Resistance(AMR) response

The Problem Orchid is Addressing



The Challenge

Antimicrobial resistance is depleting the global antibiotic arsenal faster than new drugs are being developed.



Orchid's AMS Division

An active Antimicrobial Stewardship division to focused on fighting AMR In India — through product access, education and responsible use programmes.

Antimicrobial stewardship

- AMS awareness and SOP implementation in hospitals
- Education and responsible antibiotic use

Product basket

- Orblicef
- Ortaro
- Orzid-AV
- Ceftolozane

The Committed Project

Cefiderocol

Next-generation siderophore cephalosporin- active against the most resistant gram-negative bacteria where other antibiotics fail



\$20-25 Mn
Project investment committed



1 Mn
Vials - capacity being built



Gen 5
Beyond standard cephalosporin classes

Orchid's Access Pricing Strategy

\$150

Current market price per vial

Significant cost reduction target

Making Cefiderocol accessible to markets currently priced out at global rates



Why this matters for Orchid



New product category - Cefiderocol extends Orchid's range into the most resistant cases



Reinforces AMR credibility – positions Orchid as an anti-infective innovator, not just an API manufacturer



Access pricing- significantly lower than regulated markets with cost plus pricing basis


Selective Expansion Beyond Cephalosporins

Next 5 Years

90%
Cephalosporin-led

The core cephalosporin opportunities remains the priority.

Focus Pyramid



Merger Synergy



Dhanuka's API-FDF assets in non-cephalosporin generics provide a ready physical base - selective expansion does not start from zero.

The Three Adjacencies - Ranked by Commitment



Non-Cephalosporin Generics

Physical infrastructure available through the Dhanuka Merger

Existing infrastructure & asset base

Assets in Place

1



Peptide Research

Capability building in peptide synthesis - natural adjacency to cephalosporin chemistry. Medium-term horizon.

Advanced chemistry capabilities

Early Research

2



Biotech - Fermentation



Long-term exploratory R&D. No near-term revenue expectation. Capability optionality only.

R&D optionality platform

Exploratory


3

Capital Allocation and Growth Priorities



Closing Message

Building a differentiated long-term position in critical antibiotics.



The turnaround is complete. The platform is being built. The ambition is clear.



